STERIS FY2025: Revenue Growth Accelerates to 6.2% Amid Business Transformation

What happened

STERIS generated $5.46 billion in revenue for fiscal 2025, an increase of 6.2% from the prior year's $5.14 billion. Recurring revenue streams—consumables and services—drove the growth, with consumable revenues climbing 12.2% to $1.69 billion and service revenues rising 9.0% to $2.59 billion. Capital equipment revenues declined 6.0% to $1.19 billion. Geographically, U.S. revenues increased 6.8% to $4.01 billion, representing 73% of total revenue. The Healthcare segment contributed $3.88 billion, up 7.4%, benefiting from the BD asset acquisition completed in August 2023 and organic volume gains. The AST segment posted $1.04 billion, up 8.9%, driven by mid-single digit pricing gains and volume expansion. Life Sciences declined 5.1% to $542 million, primarily due to the April 2024 divestiture of the CECS business, which generated $35 million in fiscal 2024 revenue. Gross profit expanded to $2.40 billion with margin reaching 44.0%, up 80 basis points. The improvement reflected favorable pricing (130 bps), favorable product mix (70 bps), material cost savings (30 bps), and productivity gains (20 bps), partially offset by inflationary labor and overhead pressures (150 bps). Operating income before adjustments increased 7.1% to $1.27 billion. However, total operating income increased only 3.7% to $866.6 million due to a $48.2 million settlement charge related to Illinois EO litigation and $62.3 million in restructuring expenses. The company recorded $184.7 million in income tax expense at a 23.2% effective rate, up from 21.3% in the prior year due to changes in discrete items. Operating cash flow strengthened to $1.15 billion from $973 million, and free cash flow improved to $787 million from $620 million, reflecting better working capital management. The company deployed capital to reduce debt by $1.16 billion, repurchase $200 million of shares, and increase dividends to $219.9 million.

Why it matters for investors

The fiscal 2025 results demonstrate STERIS's successful execution of its portfolio optimization strategy while maintaining operational momentum. The 6.2% revenue growth, anchored by robust recurring revenue expansion (9-12% growth in consumables and services), signals strengthening customer relationships and durable demand in core infection prevention and sterile processing markets. The company's decision to divest the Dental segment for $787.5 million and the CECS business for $41.9 million, while deploying proceeds to deleverage, materially improves financial flexibility. The debt-to-total capital ratio declined from 33.7% to 23.6%, positioning STERIS to pursue strategic acquisitions or return additional capital to shareholders. However, profitability faces near-term headwinds. The 130-basis-point margin expansion reflects pricing power and operational discipline, but the company absorbed $48.2 million in EO litigation costs and $62.3 million in restructuring charges, constraining operating income growth to 3.7%. The AST segment's margin compression from 46.1% to 44.8%, despite strong revenue growth, highlights persistent labor inflation and productivity challenges in contract sterilization operations. Management's restructuring plan, targeting $25 million in annual operating income improvements beginning fiscal 2026, addresses structural inefficiencies in the European Healthcare surgical business and product portfolio. The 27% free cash flow expansion to $787 million is particularly noteworthy, as it funded both deleveraging and $200 million in share buybacks without constraining investment. The company maintained consistent dividend growth, raising the quarterly payout to $0.57 per share. Looking forward, STERIS faces regulatory uncertainty around ethylene oxide sterilization, a critical modality for medical device processing. The $48.2 million settlement represents a substantial but potentially manageable resolution of legacy Illinois claims, though additional EO-related litigation risk persists. The company's diversified sterilization platform—including gamma, e-beam, and X-ray technologies—provides strategic hedging, but any regulatory curtailment of EO could disrupt both AST operations and Healthcare customer demand for sterile processing services.

Key highlights

STERIS completed a significant portfolio transformation during fiscal 2025, divesting the Dental segment for $787.5 million and the CECS business for $41.9 million while integrating BD surgical instrumentation assets acquired for $539.8 million in August 2023. The company executed approximately 300 headcount reductions under a restructuring plan targeting $25 million in annual operating income improvements, primarily in the European Healthcare surgical business, with the majority of benefits expected in fiscal 2026. U.S. revenues of $4.01 billion represented 73% of total revenue, up 6.8%, while international markets grew more modestly due to softness in Canada and currency headwinds. The Healthcare segment's backlog increased to $369.2 million from $353.8 million, and the Life Sciences backlog rose to $83.7 million from $71.4 million, indicating stabilizing future demand. The company maintained compliance with all debt covenants and held $1.05 billion in unused credit facility capacity at March 31, 2025, alongside $34.8 million in outstanding revolving credit borrowings. Interest expense declined $58.1 million to $86.3 million due to lower debt principal and favorable floating rate dynamics. The company recorded goodwill of $4.0 billion and intangible assets of $2.0 billion as of March 31, 2025, with no impairment charges during the year.

Management commentary

Management emphasized that fiscal 2025 operating income growth of 7.1% before adjustments demonstrates the underlying strength of the business model, though reported operating income growth of 3.7% reflects the impact of one-time EO litigation settlement costs and elevated restructuring expenses. The company highlighted that the Illinois EO settlement, while representing a material $48.2 million charge, is expected to resolve substantially all personal injury claims pending in Cook County, providing clarity on a key litigation overhang. Management stated that the restructuring plan, which incurred $62.3 million in fiscal 2025 charges and $106.7 million cumulatively since inception, is designed to enhance profitability and improve efficiency, with approximately $25 million in annual operating income improvements anticipated beginning in fiscal 2026. The company noted that it does not expect to be subject to the Corporate Alternative Minimum Tax (CAMT) through fiscal 2025, but flagged that Global Anti-Base Erosion (GloBE) rules could subject the company to additional income taxes in jurisdictions where the effective corporate tax rate falls below 15%. Management indicated that geopolitical instability, including tariff changes and trade policy shifts, creates uncertainty around production costs, supply chain continuity, and long-term investment planning, though specific quantitative impacts were not disclosed. The company stated that it expects to continue paying quarterly cash dividends for the foreseeable future, having increased the dividend each consecutive year since 2005, and that the fiscal 2025 increase to $0.57 per share reflects confidence in cash generation. Management highlighted that capital expenditures of $370.1 million in fiscal 2025 supported facility expansions in Healthcare and AST segments, and that similar investment levels are planned for fiscal 2026 to support ongoing capacity expansion.

What to watch next

Investors should monitor:

• Monitor AST segment margin trajectory in fiscal 2026, as labor inflation and productivity challenges compressed operating margin 130 basis points to 44.8% despite strong revenue growth, and assess whether management's restructuring actions stabilize profitability.

• Track resolution of ongoing EO litigation beyond the Illinois settlement, including potential additional claims, regulatory developments around EO emissions standards, and any impact on AST contract sterilization capacity or customer demand for EO-sterilized medical devices.

• Evaluate capital equipment revenue trends, particularly in Healthcare and Life Sciences segments, where fiscal 2025 declines of 5-24% may signal extended customer replacement cycles or budget constraints that could persist into fiscal 2026.

• Assess the impact of Global Anti-Base Erosion (GloBE) tax rules on effective tax rate beginning fiscal 2026, as multiple jurisdictions have adopted or are expected to adopt 15% minimum tax regimes that could increase consolidated tax expense.

This summary is based solely on excerpts from the company's Form 10-K filing.